MARKET

VIRX

VIRX

Viracta Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.51
-0.19
-2.18%
After Hours: 8.87 +0.36 +4.23% 19:31 04/09 EDT
OPEN
8.87
PREV CLOSE
8.70
HIGH
8.96
LOW
8.46
VOLUME
220.42K
TURNOVER
--
52 WEEK HIGH
24.80
52 WEEK LOW
3.920
MARKET CAP
314.87M
P/E (TTM)
-1.4751
1D
5D
1M
3M
1Y
5Y
Viracta Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
SAN DIEGO, April 8, 2021 /PRNewswire via COMTEX/ -- SAN DIEGO, April 8, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision...
PR Newswire - PRF · 2d ago
Xoma is on course for a multi-year high
XOMA Corporation ([[XOMA]] +20.5%) has gained more than a fifth of its value and if the rally holds, the stock could end up with its biggest one-day gain since September
Seekingalpha · 03/26 18:27
Viracta Therapeutics is ‘an oncology diamond’: Evercore ISI
Calling the company ‘an oncology diamond,’ Evercore ISI has initiated coverage on Viracta Therapeutics ([[VIRX]] +11.5%) with an outperform rating. Its lead program for the treatment of relapsed/refractory (R/R) EBV+
Seekingalpha · 03/25 15:56
DJ Viracta Therapeutics Price Target Announced at $45.00/Share by Evercore ISI Group
Dow Jones · 03/25 14:08
DJ Viracta Therapeutics Initiated at Outperform by Evercore ISI Group
Dow Jones · 03/25 14:08
AstraZeneca’s updated data to address integrity issue; Vertex moves to focus list at Citi in today’s analyst action
Updated interim data provided by AstraZeneca (AZN) yesterday from its late-stage COVID-19 vaccine trial in the U.S., should address the data integrity issue, UBS wrote in a note. AstraZeneca ADRs are
Seekingalpha · 03/25 13:00
LITE, NBIX, CIDM and VIRX among premarket gainers
Pieris Pharmaceuticals (PIRS) +46% on collaboration with Seagen.Houston Wire & Cable Company (HWCC) +41% on being acquired by OmniCable for $5.30 per share.Cellect Biotechnology (APOP) +41% on a definitive merger agreement with Quoin
Seekingalpha · 03/25 12:20
--Analyst Actions: Evercore ISI Starts Viracta Therapeutics at Outperform with $45 Price Target
MT Newswires · 03/25 11:32
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VIRX. Analyze the recent business situations of Viracta Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VIRX stock price target is 25.94 with a high estimate of 45.00 and a low estimate of 5.25.
EPS
Institutional Holdings
Institutions: 75
Institutional Holdings: 7.19M
% Owned: 19.44%
Shares Outstanding: 37.00M
TypeInstitutionsShares
Increased
8
39.47K
New
9
181.90K
Decreased
4
151.68K
Sold Out
4
203.64K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.53%
Pharmaceuticals & Medical Research
+0.26%
Key Executives
President/Chief Executive Officer
Ivor Royston
Chief Financial Officer/Chief Operating Officer/Secretary
Daniel Chevallard
Executive Vice President
Adam Craig
Other
Lisa Rojkjaer
Independent Director
Matthew Fust
Independent Director
Nicole Onetto
Independent Director
Stephen Rubino
Independent Director
Barry Simon
No Data
About VIRX
Viracta Therapeutics, Inc., formerly Sunesis Pharmaceuticals, Inc., is a biopharmaceutical company. The Company focuses on the development of targeted inhibitors for the treatment of hematologic and solid cancers. The Company’s lead programs are Vecabrutinib, a selective non-covalent inhibitor of Bruton’s Tyrosine Kinase (BTK) inhibitors is in Phase Ib/II clinical trial. The Company is also developing SNS-510, a phosphoinositide dependent protein kinase 1 (PDK1) inhibitor and TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. The Company also offers Vosaroxin, an anticancer quinolone derivative (AQD), which is used for the treatment of acute myeloid leukemia (AML).

Webull offers kinds of Viracta Therapeutics Inc stock information, including NASDAQ:VIRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIRX stock methods without spending real money on the virtual paper trading platform.